Undisclosed gene promoter activated via RNAa

Undisclosed gene promoter activated via RNAa is a placeholder designation for a therapeutic target whose specific identity is proprietary and has not been publicly revealed by the developing entity. This target is typically a gene promoter that is selectively upregulated through the mechanism of RNA activation (RNAa), which utilizes small activating RNAs (saRNAs) to induce the transcription of a specific gene [4, 10]. RNAa works by targeting promoter-associated transcripts or the promoter DNA itself, recruiting transcriptional activation complexes that lead to increased mRNA and protein production [10, 17]. This technology is primarily employed to restore the expression of tumor suppressors, metabolic enzymes, or other proteins that are deficient in various diseases [3, 11]. Such targets are common in the pipelines of companies like MiNA Therapeutics and Ractigen Therapeutics, often in collaboration with larger pharmaceutical partners like AstraZeneca or Servier for indications in oncology, metabolic disorders, and rare genetic diseases [15, 17]. Because the target is undisclosed, its specific biological role and disease association are defined by the proprietary program, though the overarching goal is the therapeutic upregulation of a beneficial endogenous protein [3, 8].

Other names

Undisclosed saRNA targetUndisclosed RNA activation targetProprietary RNAa target

RNA activation (RNAa) utilizes small activating RNAs (saRNAs) to target specific sequences within a gene's promoter or promoter-associated transcripts. This interaction recruits the RNA-induced transcriptional activation (RITA) complex, leading to epigenetic modifications and the recruitment of RNA polymerase II, which enhances the transcription of the target gene.